查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1819916

2025-2033 年藥物基因組學市場（按技術、應用、最終用戶和地區）報告

Pharmacogenomics Market Report by Technology, Application, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 141 Pages | 商品交期: 2-3個工作天內

價格

2024 年全球藥物基因體學市場規模達 86 億美元。展望未來， IMARC Group預計到 2033 年市場規模將達到 170 億美元，2025-2033 年期間的成長率 (CAGR) 為 7.55%。

藥物基因體學是研究人類基因對特定藥物反應的遺傳變異的學科。它利用藥理學和基因組學的原理，開發根據個體基因組成客製化的有效且安全的藥物。它涉及多種技術，例如聚合酶鍊式反應 (PCR)、微陣列、脫氧核糖核酸 (DNA) 定序、質譜和電泳。藥物基因組學中進行的基因檢測有助於確定對某些疾病的易感性以及新開發藥物的療效。藥物基因組學也廣泛應用於各種疾病的治療，例如心血管疾病、阿茲海默症、癌症、人類免疫缺陷病毒和後天免疫缺乏症候群 (HIV/AIDS) 以及氣喘。

藥物基因組學市場趨勢：

全球製藥業的顯著成長是市場前景樂觀的關鍵因素之一。此外，對安全性更高的精準醫療的需求日益成長，也推動了市場的成長。隨著慢性生活方式疾病的日益流行，副作用最小、療效較佳的標靶藥物療法已被廣泛應用。同時，藥物基因組學也廣泛應用於癌症治療，並用於預測化療和標靶免疫生物製劑的潛在藥物反應、抗藥性、療效和毒性，這也促進了市場的成長。此外，各種技術進步，例如藥物基因組學生物標誌標記解決方案的開發，也成為其他成長誘導因素。它們有助於最大限度地降低體內可避免的藥物不良反應 (ADR) 的風險，並改善臨床療效。其他因素，包括廣泛的研發活動以及醫療保健基礎設施的顯著改善，預計將推動市場成長。

本報告回答的關鍵問題

  • 藥物基因組學市場有多大？藥物基因組學市場未來前景如何？
  • 推動藥物基因體學市場發展的關鍵因素有哪些？
  • 全球藥物基因組學市場領先的公司有哪些？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 二手資料
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球藥物基因體學市場

  • 市場概況
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依技術

  • 聚合酶鍊式反應
  • 微陣列
  • DNA定序
  • 質譜法
  • 電泳
  • 其他

第7章：市場區隔：依應用

  • 腫瘤學
  • 傳染病
  • 心血管疾病
  • 神經系統疾病
  • 精神病學
  • 疼痛管理
  • 其他

第 8 章：市場區隔：依最終用戶

  • 醫院和診所
  • 學術及研究機構

第9章：市場細分：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第 10 章：SWOT 分析

第 11 章：價值鏈分析

第 12 章：波特五力分析

第13章：價格分析

第 14 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • AstraZeneca plc
    • Bayer AG
    • Becton Dickinson and Company
    • Bio-Rad Laboratories Inc.
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline plc
    • Illumina Inc.
    • Johnson & Johnson
    • Merck KGaA
    • Myriad Genetics Inc.
    • Qiagen NV
    • Thermo Fisher Scientific Inc
Product Code: SR112025A4396

The global pharmacogenomics market size reached USD 8.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 17.0 Billion by 2033, exhibiting a growth rate (CAGR) of 7.55% during 2025-2033.

Pharmacogenomics is the study of inherited variations in human genes in response to specific drugs. It utilizes the principles of pharmacology and genomics to develop effective and safe medications that are customized to the genetic makeup of an individual. It involves the use of various technologies, such as polymerase chain reaction (PCR), microarray, deoxyribonucleic acid (DNA) sequencing, mass spectrometry and electrophoresis. The genetic tests performed in pharmacogenomics aid in determining the susceptibility to certain diseases and efficacy of the newly developed drugs. Pharmacogenomics is also widely used in the treatment of various diseases, such as cardiovascular, Alzheimer's, cancer, human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS) and asthma.

Pharmacogenomics Market Trends:

Significant growth in the pharmaceutical industry across the globe is one of the key factors creating a positive outlook for the market. Moreover, the increasing demand for precision medicines with enhanced drug safety is providing a thrust to the growth of the market. With the increasing prevalence of chronic lifestyle diseases, there is widespread adoption of targeted drug therapies with minimal side effects and improved efficacy. In line with this, pharmacogenomics is also extensively used for cancer treatments and anticipating the possible drug responses, resistance, efficacy and toxicity of the chemotherapeutic and targeted immune biologic agents, which is also contributing to the market growth. Additionally, various technological advancements, such as the development of pharmacogenomic biomarker labeling solutions, are acting as other growth-inducing factors. They aid in minimizing the risks of avoidable adverse drug reactions (ADRs) in the body and improve clinical outcomes. Other factors, including extensive research and development (R&D) activities, along with significant improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.

Key Market Segmentation:

Breakup by Technology:

  • Polymerase Chain Reaction
  • Microarray
  • DNA Sequencing
  • Mass Spectrometry
  • Electrophoresis
  • Others

Breakup by Application:

  • Oncology
  • Infectious Diseases
  • Cardiovascular Diseases
  • Neurological Diseases
  • Psychiatry
  • Pain Management
  • Others

Breakup by End User:

  • Hospitals and Clinics
  • Academic and Research Institutes

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AstraZeneca plc, Bayer AG, Becton Dickinson and Company, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Illumina Inc., Johnson & Johnson, Merck KGaA, Myriad Genetics Inc., Qiagen N.V. and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

  • 1.How big is the pharmacogenomics market?
  • 2.What is the future outlook of pharmacogenomics market?
  • 3.What are the key factors driving the pharmacogenomics market?
  • 4.Which are the leading companies in the global pharmacogenomics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pharmacogenomics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Polymerase Chain Reaction
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Microarray
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 DNA Sequencing
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Mass Spectrometry
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Electrophoresis
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Oncology
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Infectious Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cardiovascular Diseases
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Neurological Diseases
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Psychiatry
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Pain Management
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Academic and Research Institutes
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Becton Dickinson and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Bio-Rad Laboratories Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 F. Hoffmann-La Roche AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 SWOT Analysis
    • 14.3.7 GlaxoSmithKline plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Illumina Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Johnson & Johnson
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Merck KGaA
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Myriad Genetics Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Qiagen N.V.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13 Thermo Fisher Scientific Inc
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Pharmacogenomics Market: Major Drivers and Challenges
  • Figure 2: Global: Pharmacogenomics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Pharmacogenomics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Pharmacogenomics Market: Breakup by Technology (in %), 2024
  • Figure 5: Global: Pharmacogenomics Market: Breakup by Application (in %), 2024
  • Figure 6: Global: Pharmacogenomics Market: Breakup by End User (in %), 2024
  • Figure 7: Global: Pharmacogenomics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Pharmacogenomics (Polymerase Chain Reaction) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Pharmacogenomics (Polymerase Chain Reaction) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Pharmacogenomics (Microarray) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Pharmacogenomics (Microarray) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Pharmacogenomics (DNA Sequencing) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Pharmacogenomics (DNA Sequencing) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Pharmacogenomics (Mass Spectrometry) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Pharmacogenomics (Mass Spectrometry) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Pharmacogenomics (Electrophoresis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Pharmacogenomics (Electrophoresis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Pharmacogenomics (Other Technologies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Pharmacogenomics (Other Technologies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Pharmacogenomics (Oncology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Pharmacogenomics (Oncology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Pharmacogenomics (Infectious Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Pharmacogenomics (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Pharmacogenomics (Cardiovascular Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Pharmacogenomics (Cardiovascular Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Pharmacogenomics (Neurological Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Pharmacogenomics (Neurological Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Pharmacogenomics (Psychiatry) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Pharmacogenomics (Psychiatry) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Pharmacogenomics (Pain Management) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Pharmacogenomics (Pain Management) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Pharmacogenomics (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Pharmacogenomics (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Pharmacogenomics (Hospitals and Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Pharmacogenomics (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Global: Pharmacogenomics (Academic and Research Institutes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Global: Pharmacogenomics (Academic and Research Institutes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: North America: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: North America: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: United States: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: United States: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Canada: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Canada: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Asia-Pacific: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Asia-Pacific: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: China: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: China: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Japan: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Japan: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: India: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: India: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: South Korea: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: South Korea: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Australia: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Australia: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Indonesia: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Indonesia: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Others: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Others: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Europe: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Europe: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Germany: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Germany: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: France: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: France: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: United Kingdom: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: United Kingdom: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Italy: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Italy: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Spain: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Spain: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Russia: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Russia: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Others: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Others: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Latin America: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Latin America: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Brazil: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Brazil: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Mexico: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Mexico: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Others: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Others: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Middle East and Africa: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 85: Middle East and Africa: Pharmacogenomics Market: Breakup by Country (in %), 2024
  • Figure 86: Middle East and Africa: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Global: Pharmacogenomics Industry: SWOT Analysis
  • Figure 88: Global: Pharmacogenomics Industry: Value Chain Analysis
  • Figure 89: Global: Pharmacogenomics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pharmacogenomics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Pharmacogenomics Market Forecast: Breakup by Technology (in Million USD), 2025-2033
  • Table 3: Global: Pharmacogenomics Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 4: Global: Pharmacogenomics Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 5: Global: Pharmacogenomics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Pharmacogenomics Market: Competitive Structure
  • Table 7: Global: Pharmacogenomics Market: Key Playe